Sector News

Sanofi to buy Kadmon for $1.9B, extending deal streak

September 12, 2021
Life sciences

Sanofi has agreed to buy Kadmon Holdings for $1.9 billion, the latest in a string of acquisitions the French pharmaceutical giant has used to add new drugs and technologies to its portfolio.

The deal, announced Wednesday, has Sanofi paying $9.50 per share in cash for Kadmon, a roughly 77% premium to the biotech’s Tuesday closing price and 113% more than its average trading price over the last two months. The acquisition gives Sanofi rights to Rezurock, a drug for graft-versus-host disease the Food and Drug Administration approved in July.

The buyout is the sixth largest, and features the third highest premium, in what’s been a comparatively slow year for biotech buyouts, according to data from Biopharma Dive. It’s also the sixth acquisition by Sanofi since the beginning of last year, a flurry of activity worth some $10 billion and the most of any pharmaceutical company over that span.

Those deals have given Sanofi a variety of different assets, from a messenger RNA vaccine platform to “off-the-shelf” cell therapies, and together represent a push by the drugmaker to remake itself after pivoting from the cardiovascular and diabetes research for which it’s long been known. READ MORE

By Ben Fidler


comments closed

Related News

February 4, 2023

MedTrace receives U.S. patent for diagnosing the human heart

Life sciences

The U.S. Patent and Trademark Office issued a patent to MedTrace for their method of diagnosing the human heart via 15O-water PET. The patented method is the foundation of the company’s software aQuant, currently under development. Hendrik “Hans” Harms, PhD and Senior Scientist at MedTrace, and Jens Soerensen, Professor and Clinical Advisor to MedTrace, are the originators of the method.

February 4, 2023

Roche taps insider Teresa Graham for top pharma job as setbacks prompt M&A questions

Life sciences

Teresa Graham, currently head of global product strategy for Roche pharma, will become the division’s new CEO next month, Roche said Thursday. Simultaneously, Roche is elevating Levi Garraway, chief medical officer, to the executive committee.

February 4, 2023

J&J’s pharma group quietly works through global overhaul, with layoffs expected to reach multiple countries

Life sciences

Fierce Pharma has obtained internal documents and video of a town hall meeting conducted this week describing what J&J called a “comprehensive review” of its portfolio. Moving forward, J&J plans to operate its vaccines and infectious diseases outfits as one group, the executives explained.

How can we help you?

We're easy to reach